2019 American Society of Hematology Annual Meeting*

December 7-10, 2019; Orlando, Florida
Review slidesets and analyses of key data from the 2019 Hematology meeting.

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Capsule Summary Slidesets

Initial results from ongoing phase II study suggest clinical activity of luspatercept in patients with MF-associated anemia.

Released: December 8, 2019

Venetoclax alone or in combination with azacitidine was well tolerated in patients with relapsed/refractory MDS, with combination therapy achieving an ORR of 40% and estimated 12-month OS of 65%.

Released: December 19, 2019

In patients with TP53-mutant MDS/AML, APR-246 plus azacitidine was active and generally well tolerated.

Released: December 19, 2019

Interim findings demonstrate that APR-246 yields a high CR rate when combined with azacitidine in patients with MDS or AML with TP53 mutations.

Released: December 19, 2019

Longer-term analysis of the MEDALIST study showed that more luspatercept-treated patients attained transfusion independence for ≥ 8 weeks any time during therapy compared with placebo.

Released: December 15, 2019
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue